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Abstract Detection and investigation of congenital
anomaly clusters is one part of surveillance to detect new
or changing teratogenic exposures in the population. The
EUROCAT (European Surveillance of Congenital Ano-
malies) cluster monitoring system and results are described
here. Monitoring was conducted annually from 2007 to
2013 for 18 registries covering an annual birth population
up to 0.5 million births. For each registry and 72 anomaly
subgroups, the scan ‘‘moving window’’ technique was used
to detect clusters in time occurring within the last 2 years
based on estimated date of conception. Registries con-
ducted preliminary investigations using a standardised
protocol to determine whether there was cause for concern,
and expert review was used at key points. 165 clusters were
detected, a rate of 3.4 % of all 4823 cluster tests performed
over 7 years, more than expected by chance. Preliminary
investigations of 126 new clusters confirmed that 35 %
were an unusual aggregation of cases, while 56 % were
explained by data quality or diagnostic issues, and 9 %
were not investigated. For confirmed clusters, the reg-
istries’ course of action was continuing monitoring. Three
confirmed clusters continued to grow in size for a limited
period in subsequent monitoring. This system is best suited
to early detection of exposures which are sudden, wide-
spread and/or highly teratogenic, and was reassuring in
demonstrating an absence of a sustained exposure of this
type. Such proactive monitoring can be run efficiently
without overwhelming the surveillance system with false
positives, and serves an additional purpose of data quality
control.
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Introduction
The thalidomide epidemic in the early 1960s, when more
than 10,000 babies worldwide were born with major con-
genital anomalies due to early pregnancy exposure to the
medication thalidomide [1], was a seminal event for both
congenital anomaly (CA) surveillance and pharma-
covigilance. European Surveillance of Congenital Anoma-
lies (EUROCAT) was set up in its wake, with a focus on the
early detection of any new epidemic of CA related to ter-
atogenic exposure [2]. Now, more than 50 years after
thalidomide, EUROCAT covers nearly one-third of the
5 million births annually in the European Union (EU). The
interest of surveillance has widened to other environmental
exposures beyond medications, in particular environmental
pollutants. Electronic data transfer and linkage, greater
computing power, and new statistical methodology have
presented new opportunities for the conduct of surveillance.
At the core of CA surveillance is the regular and sys-
tematic detection of increasing trends and clusters in time,
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to detect potential concerns where there is no prior hy-
pothesis about the exposure, an activity EUROCAT terms
‘‘Statistical Monitoring’’ [3, 4]. This may provide the first
clue to a teratogenic exposure, eventually leading to a
preventive intervention which can stop the increase in
frequency continuing or reoccurring. Nevertheless, outside
of applications in infectious disease control and bio-
surveillance, cluster detection has been a controversial area
in public health practice [4–6], with concerns that it could
overwhelm a public health system with chance clusters [5,
6], that it is difficult to distinguish clusters with a common
causal agent from chance clusters or find that common
cause [7], that routine detection systems are too slow to
detect increases [5], and that cluster detection methods are
poorly characterised in terms of their power to detect
clusters of interest [8].
In this paper, we present the EUROCAT approach to the
detection and investigation of temporal clusters, and the
results to date. The routine assessment of trends which also
forms part of EUROCAT statistical monitoring has been
described previously [3], and the statistical methods for
cluster detection are presented in full in an accompanying
paper [9].
Methods
EUROCAT registries and database
EUROCAT registries are population-based, and cover
livebirths, fetal deaths from 20 weeks gestational age
(GA), and terminations of pregnancy for fetal anomaly.
Registries use multiple sources of case ascertainment [10],
and data quality is described and monitored by a series of
data quality indicators [11].
There are 31 full and 6 associate member EUROCAT
registries currently, covering a population of 1.6 million
births per year. Full member registry populations range
from a few small registries with\10,000 births per year, to
the majority of registries in the range 10–50,000 births, to
two registries with 75–90,000 annual births [10]. Only
registries with stable birth populations (varying\10 % per
year), and which transmit data before the set deadline, are
eligible to participate in monitoring [9, 12]. The number of
registries eligible each year is shown in Table 1. Up to 18
registries were eligible: Antwerp, Hainaut, (BE); Odense,
(DK); Isle de La Reunion, Paris, (FR); Dublin, South East
Ireland, (IE); Emilia Romagna, Tuscany, (IT); Northern
Netherlands, (NL); Vaud (CH); Ukraine (UA); East Mid-
lands and South Yorkshire, North England, South West
England, Thames Valley, Wales, Wessex (UK) EUROCAT
has a Central Registry which holds a database of anon-
ymised individual records of cases of CA for full members,
and aggregate data for associate members. The dataset of
individual records used for statistical monitoring includes
date of birth (DOB), gestational age (GA, in completed
weeks), type of birth (live, still, termination of pregnancy)
and up to nine malformations and syndromes coded to
ICD10-BPA [13].
Definition of ‘‘cluster’’ and time and spatial
dimensions
EUROCAT defines a temporal cluster as an unusual ag-
gregation of cases in time. This definition does not carry
any judgement as to whether the cluster may or may not be
a chance phenomenon. For cluster detection, an arbitrary
threshold of ‘‘unusual’’ is used (see below).
For Central Registry analysis, the spatial dimension
during the study period was operationalized as registry:
which may be a region or the whole country. Since the
study period for this paper, additional country level ana-
lyses have also been performed combining more than one
registry in the same country. During preliminary investi-
gation of time clusters, the spatial dimensions within the
registry area are further investigated, and local registries
can run the cluster detection software at subregional level.
The date of last menstrual period (LMP) calculated from
DOB and GA is used as a proxy for ‘‘date of conception’’
and is estimated for each CA case (formally, 2 weeks
should be added to LMP to arrive at estimated date of
conception, but we retain an LMP-based analysis). The
switch from DOB-based analysis to date of conception-
based analysis was made after many clusters by DOB were
found not to be clustered when considered by estimated
date of conception, particularly for anomalies where ter-
minations of pregnancy are frequent. Since we are mainly
looking for signs of early pregnancy exposure, acting
during specific developmental windows, date of conception
is the most relevant reference point. A specific protocol
deals with missing GA, including reverting to DOB-based
analysis if it is missing for more than 10 % of cases [12].
The most recent 5 years of data (by year of birth) are
included in the cluster analysis, and the resulting concep-
tion period is truncated to run from 1 January of the first
birth year (year X - 4), to 31 March of the most recent
birth year (year X) of the monitoring period. The truncation
to March 31 means that all conceptions in the most recent
year of birth will have resulted in a delivery or termination
of pregnancy within that year. Only clusters wholly or
partially occurring within the most recent 2 years (con-
ceptions 1 April year X - 2 to 31 March year X) form part
of the statistical output. Output is limited to clusters of up
to 18 months duration [9, 12].
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Statistical method and software for cluster detection
As described in full elsewhere [9, 12], the Scan (or
‘‘moving window’’) method [14, 15] runs a window of
from 5 to (n - 2) cases, where n is the total number of
cases, across the time period of analysis, and, by compar-
ison with simulated data, detects sequences of cases that
occur in a shorter time period than would be expected by
chance (p\ 0.05). Clusters of \5 cases are not sought
because experience shows that clusters of\5 cases rarely
result in a satisfactory investigation outcome [7, 16], and
these were not foreseen in the published method [14, 15].
This method is self-adjusting for multiple testing across
window sizes, but not across different registries or CA
subgroups.
A number of criteria drove the choice of statistical
method for cluster detection: (a) incorporating adjustment
for multiple testing (b) appropriate for small numbers of
cases as CA are rare (c) not requiring the prior setting of a
‘‘baseline’’ or expected rate which previous experience had
shown slows down the system due to the need for frequent
re-agreement of baselines (d) not requiring population
births data (temporal resolution below yearly birth numbers
is not universally or immediately available) (e) possible to
program in the EUROCAT Data Management Programme
(EDMP) [9, 13] with a simple interface for use by non-
statisticians and (f) relatively intuitive output for commu-
nication with public health professionals and managers.
Prospective scan methods have been advocated [17], but do
not suit our system as we update data from previous years
and only perform monitoring centrally once per year after
data transmission.
The cluster detection software is integrated within the
EUROCAT Central Database (ECD) software, and the
EDMP used by member registries, and was refined over the
years. Cluster detection output [12, 18] includes a Euro-
pean summary (from ECD), summaries for individual
registries, and outputs detailing each specific cluster.
Cluster output (Fig. 1) includes a 5 year timeline and de-
tails of the cluster with number of cases, start and end date
of estimated conception, ‘‘expected’’ number of cases
during the time period of the cluster (i.e. the average no.
cases per day multiplied by the number of days), lambda
(the scan statistics), and probability. Several clusters may
be detected with a probability of\0.05 which overlap in
time, and these are put into cluster groups [9].
Which CA subgroups are monitored?
EUROCAT uses 89 standard binary CA subgroups, auto-
matically assigned by the ECD/EDMP from ICD10-BPA
codes [13], of which 72 are monitored for clusters [12],
Table 1 Cluster detection for the period 2007–2013 by year: no. EUROCAT registries included in monitoring and their population coverage,
number of tests conducted and clusters detected, and results of cluster investigations
2007 2008 2009 2010 2011 2012 2013 Total 2007–2013
Results of cluster detection
Registries (n) 10 11 10 16 16 17 18 –
Annual population covered (no. births) 234,317 226,011 272,975 390,510 401,282 473,675 505,250 –
Cases of Congenital Anomaly (n) 11,891 10,687 12,048 16,654 18,275 22,152 23,619 –
Congenital anomaly subgroups (n) 75 75 75 76 76 73 72 –
Tests performed (n) 482 500 487 766 805 882 901 4823
Cluster detection rate (%) 2.90 3.40 4.72 3.92 2.48 3.06 3.77 3.42
Total clusters detected (n) 14 17 23 30 20 27 34 165
Newa clusters (n) 12 15 18 21 16 24 20 126
Olda clusters (n) 2 2 4 4 3 3 7 25
Continuinga Cluster (n) 0 0 1 5 1 0 7 14
Investigation results (new clusters only)
Cluster confirmed, no explanation 2 9 6 7 2 11 7 44 (34.9 %)
Cluster due to data quality issues 3 3 5 6 2 6 10 34 (27.8 %)
Cluster due to increasing prenatal diagnosis 0 0 2 1 7 0 0 10 (7.9 %)
Heterogeneous anomalies in cluster 4 3 2 3 5 6 3 26 (20.6 %)
No investigation 3 0 3 4 0 1 0 11 (8.7 %)
a New clusters are those not detected in the previous year’s monitoring, old clusters are clusters detected in the previous year’s monitoring which
have not grown in size, continuing clusters are those clusters detected in the previous year’s monitoring which have since continued and
increased in size
Congenital anomaly cluster detection 1155
123
selected by the EUROCAT Coding and Classification
Committee. Subgroups are organised at several hierarchical
levels (e.g. Spina Bifida within Neural Tube Defects, or
Down Syndrome within Chromosomal). Large heteroge-
neous subgroups (e.g. nervous system, cardiac, digestive
system) are not monitored. Cases with chromosomal or
other genetic syndromes are monitored separately from
‘‘non-genetic’’ cases. Within those categories, a case can be
counted in multiple subgroups, but only once in each
subgroup (e.g. a multiply malformed case of spina bifida
and omphalocele is counted once for spina bifida, once for
omphalocele, and once for all non-genetic).
Preliminary investigation protocol
Registries conduct ‘‘Preliminary Investigations’’ of the
clusters identified using data available in their registries,
and where necessary consulting medical records or
speaking with clinicians regarding changes in diagnostic
methods. The protocol for preliminary investigation
(Fig. 2) emphasises exploring the temporal, spatial and
diagnostic dimensions of the cluster, rather than taking too
arbitrary an approach to its boundaries. The first step is to
verify the cases included, making sure that anomalies have
been correctly coded, and that there are no hidden dupli-
cates. If the cases are verified, the registry investigates
potential changes in diagnostic or ascertainment methods
as an underlying explanation. Registries then look in their
records at recorded exposures e.g. medication, maternal
illness, assisted reproduction, unusual exposures, and de-
mographic characteristics such as age, ethnicity that might
help seek a time-related common cause.
Registries are asked to consider the cluster detected in
the light of any significant trend signalled over the same
time period, and investigate as a trend rather than cluster if
appropriate. They are alerted to the most significant cluster,
but asked to consider the full 5-year timeline and evidence
of overlapping clusters in their investigation and
interpretation.
At the end of the preliminary investigation, the registry
decides whether the cluster can be ascribed to an artefact of
diagnostic or registry practice or data quality, or requires
further monitoring or further public health investigation.
We consider a cluster ‘‘confirmed’’ if, after preliminary
Fig. 1 An example of the
EDMP statistical monitoring
output showing a cluster
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Each year, clusters are divided into “new” clusters, “continuing” clusters and “old” clusters.  
New clusters are those which have not been detected previously.  Continuing clusters are 
those which were detected the previous year but have continued in time.  These are 
particularly important to investigate.  Old clusters are those which were detected and 
investigated the previous year, but have not continued. Central Registry alerts you to new 
and continuing clusters.  Make sure that you look at the full 5-year timeline for the 
congenital anomaly subgroup of interest, as this shows the time distribution of all cases.
• Case verification
– Confirmed and accurate diagnoses?
– Duplicates?
– Confirmed to be resident within region? (truly population-based?)
• Diagnostic dimension:
– How heterogeneous are the diagnoses? Are cases isolated, multiply 
malformed, syndromes? Any family history recorded?
– Do any other anomalies have clusters at the same time?
• Space dimension:
– Are they clustered near each other within region?
– Do they come from a single hospital?
– Do other EUROCAT regions have a cluster at a similar time? 
– NB. The aim is to describe the cluster in terms of its spatial characteristics, 
giving clues as to possible causes for further investigation. For example, a 
new drug on the market may not show spatial concentration, whereas a 
local chemical pollution accident would be expected to show spatial 
concentration. 
• Time dimension:
– Is the cluster part of a longer term trend identified by the trend analysis? (if 
so, investigate as trend rather than as cluster)
– When does the increased risk appear to start and end – a longer period than 
the dates of the most statistically significant cluster itself?  Look at other 
clusters in the cluster group to get an idea of the extent of the cluster.
– Look at the five year timeline graph. Consider evidence that the cluster 
started earlier than the last 2 years of data, and observe when the greatest 
aggregation of cases occurred.
– If cluster is based on date of birth rather than date of conception, is it likely, 
making assumptions about gestational age of cases within and outside the 
cluster, that the cluster would also appear if analysed by date of 
conception? 
• Diagnostic & reporting factors: 
– Could a change in diagnostic methods, training, personnel or reporting 
practice have caused the cluster?  This might be particularly suspected if 
only one hospital is involved, and for anomaly subgroups which vary widely 
in severity
– Does the registry have a lower rate before the cluster compared to other 
registries?  Check EUROCAT website for prevalence in other registries 
(http://www.eurocat-
network.eu/ACCESSPREVALENCEDATA/PrevalenceTables)  
– If there is a very large number of cases in the cluster in a very short time 
period, it is unlikely to be due to diagnostic factors.
• Aetiological factors: 
– Which factors have been investigated within the registry database (list 
variables) and outside the registry database and do any of these appear to 
explain the cluster? – choice of factors to investigate depends on type of 
anomaly
• Local context:
– Was there local awareness of the cluster before it was found by central 
statistical monitoring, either by local EDMP monitoring or other means?
– Had anyone outside the registry in your region (e.g. local community or 
health professional) previously been aware of the cluster?
– Are there any local concerns about environmental exposures which may 
need investigation?
If investigation of clusters identifies data errors (e.g. incorrect diagnoses, incorrect dates of 
birth) these errors should be corrected and updated data included in the next data 
transmission to Central Registry. 
Recommendations:
Follow up all cluster cases to their current age for further diagnostic information and family 
history.  For clusters of chromosomal anomalies, exact karyotype should be reported for all 
cases in the cluster.  If it is not already normal practice, registries should go back to original 
medical records for cluster cases.  When a cluster is confirmed and recommended for 
continued surveillance, registries should organise to do this surveillance earlier than the 
Central Registry system.
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investigation, the aggregation of cases remains unusual.
The preliminary investigation describes the cluster (e.g. in
relation to spatial aggregation within registry area) to fa-
cilitate identifying hypotheses for further investigation if
appropriate, but does not conclude on or assess causality.
Timeliness and process
Registries are included in statistical monitoring if they
transmit their data for year X by February of year X ? 2
(e.g. data for births in 2011 were transmitted by February
2013). This allows for postneonatal diagnosis, and for a
good level of completion of case finding and data cleaning.
Central Registry confirms data with member registries,
runs validation checks and then runs statistical monitoring
in early April.
The statistical monitoring output is assessed by a com-
mittee comprising epidemiologists, clinical geneticists,
clinicians and a statistician, and including the EUROCAT
Steering Committee, in mid April. The output along with
their advice and a response template is sent to registries,
who present their results at the Annual Registry Leaders
Meeting in June of each year. The draft Annual Statistical
Monitoring Report is discussed by the Committee, and
approved by registries, before publication. Information
available to the public observes data protection require-
ments concerning potential identification of individual
cases.
Analysis of cluster data in annual monitoring
2007–2013
The monitoring system was first run in 2003 for data up to
birth year 2001, and significant adjustments in method-
ology were made until 2006. We report here the results of
statistical monitoring run each year from 2007 to 2013.
According to whether they had been identified in the
previous year’s monitoring, clusters were classified as
‘‘new’’, ‘‘continuing’’ (increased in time and number of
cases) or ‘‘old’’ (unchanged). ‘‘New’’ clusters may be in
year X - 1 rather than in year X if the registry was not
included in the monitoring analysis the previous year, if the
statistical significance of findings shifted as the 5 year time
period shifted, or if registration data for year X - 1 had
been updated since the previous monitoring analysis.
Each scan test can identify more than one significant
cluster [9], but for simplicity of presentation, we consider
here only the most significant cluster from each scan test.
EUROCAT registries follow the ethics approval
guidelines of their countries, and the EUROCAT Central
Registry activities have ethics approval from Ulster
University.
Results
The annual results for the 7 years of annual monitoring
from 2007 to 2013 (up to birth year 2011) are shown in
Table 1. Across the 7 years, 165 (3.4 %) of all 4,823
cluster tests performed resulted in statistically significant
clusters being detected. Of these 165, 126 (76 %) were
‘‘new’’, 14 (8 %) were ‘‘continuing’’ and 25 (15 %) were
‘‘old’’ (Table 1). Ten of the 165 clusters were from date of
birth-based tests. There were no instances of the same CA
subgroup appearing as a cluster in a similar time period in
two or more registries.
In the most recent year, 2013, 18 registries were in-
cluded in monitoring covering an annual birth population
of over 500,000 births (Table 1). In that 1 year, a total of
901 scan tests were performed, of which 3.8 % indicated a
significant cluster, a total of 34 clusters.
Over the 7 year period, 126 ‘‘new’’ clusters were sent to
registries for preliminary investigation. Of these, 9 % were
not investigated by registries (Table 1), 21 % were con-
sidered to be diagnostically heterogeneous, 8 % were
considered to be explained by changes in prenatal screen-
ing/diagnostic methods, and 28 % were considered to be
explained by data quality issues (including duplicate cases,
miscoding, changes in case ascertainment methods or in-
clusion criteria, or more accurate local data on LMP). For
35 % (44 clusters), the cluster was ‘‘confirmed’’ as an
unusual aggregation. None of these clusters related to si-
tuations where there were any pre-existing environmental
concerns in the registry area which might form a focus for
investigation, nor did registry records identify any common
exposures.
Most of the 44 confirmed new clusters involved 5–9
cases (Tables 2, 3). All four clusters with Observed/Ex-
pected ratio of 20 or more were of duration 1–2 days
(Table 3). Five clusters were associated with a probability
\0.001 (Tables 2, 3).
Of the 44 confirmed new clusters, 26 occurred wholly or
partially within the most recent year of data (year X) with
the registry recommending further monitoring rather than
moving to a more extensive public health investigation. In
the subsequent year of monitoring, 15 of these 26 reap-
peared as the same cluster, now classified as ‘‘old’’, five
were no longer statistically significant in the shifted 5 year
period of the next year’s monitoring, and three were not re-
evaluated as the registries concerned were not participat-
ing. Three of the 26 recent confirmed new clusters became
‘‘continuing clusters’’ in subsequent monitoring.
Eighteen of the 44 confirmed new clusters occurred in
year (X - 1). For five of these clusters, the registry had not
participated the previous year. Updating of year (X - 1)
data with late registrations was the most probable
1158 H. Dolk et al.
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explanation for the majority, but this could not be checked
as timelines were only archived in case of significant
clusters.
The scan test was usually picking up unusual aggrega-
tions not signalled by the trend analyses. Two of the 44
new confirmed clusters occurred against a background of a
significant decreasing trend, and two occurred in asso-
ciation with an increasing trend and may have been a
manifestation of that trend. For the remaining 40 clusters,
either there was no significant trend (n = 22), or significant
non-linear change (n = 6), or the numbers were too low for
a trend test (n = 12) [Table 3].
Of the 14 continuing clusters detected in the 7 years of
monitoring, 11 concerned situations where the original
cluster had been explained by diagnostic, reporting or data
quality issues, but it had not been possible to correct the
data appropriately. Three were continuations of confirmed
new clusters. One cluster of six cases of congenital cataract
was first detected in 2008, with LMPs occurring in Feb–
March of 2006, reappeared as an ‘‘old’’ cluster in 2009, and
in 2010 increased in size by one case with LMP in April
2006. Due to the delay, no special attention was given to
the continuation. One cluster of seven cases of asplenia was
first detected in 2008, the registry did not participate in
monitoring the next year, and in 2010 the cluster had
grown to 11 cases. Again due to the delay no special at-
tention was given. Finally, a cluster of six cases of clubfoot
was detected in 2013 with LMPs in August 2010, had
grown to 72 cases by 2014 with LMP from Sept 2009 to
Feb 2011 (O/E 1.7, p\ 0.001), and has been notified to the
relevant national public health authority with as yet no
further news.
Discussion
During the 7 years of monitoring by EUROCAT
2007–2013, cluster detection revealed no evidence of a
widespread, sudden and sustained temporal increase in CA
potentially caused by a new teratogenic exposure. This
cluster detection approach allows the existence of previ-
ously unsuspected or unrecorded exposures to be signalled,
but is unlikely to detect the presence of teratogens of low
potency [19], or teratogens with very restricted exposure
such as medications for infrequent diseases or exposures in
a small part of the geographical population. Other
surveillance activities are needed in parallel, which tend to
be more productive in terms of aetiologic findings. These
include hypothesis generating screening of CA association
with specific exposures or exposure sources (e.g. medica-
tions in pharmacovigilance [20], pollution sources or pol-
lutants in envirovigilance) [21], and the testing of
hypotheses with specifically designed studies based on the
routinely collected registry data [22–24], and case–control
surveillance investigating a wide range of potential ae-
tiologic agents [24, 25].
We have not proceeded to detection of spatial clusters as
this may be more appropriately done at regional or national
level, and we consider spatial analyses of specific pollution
sources [21, 26, 27] to be a more productive investment of
resources than spatial cluster detection without prior hy-
pothesis [28]. Moreover, fine spatial level analyses have
more stringent data protection requirements which are
difficult to achieve at European level currently.
Rothman advocated strongly [7] that cluster response
should not be pursued as a public health activity, since
most clusters would be chance unusual aggregations, and it
is difficult to distinguish the few non-chance clusters and
identify their causes, particularly when the number of cases
is small. On the other hand, public health authorities are
expected by the public to respond to suspected clusters
with appropriate action [5, 6, 29]. Our experience suggests
that a proactive approach to detecting and responding to
clusters can be successful, rather than a reactive approach
which responds to clusters identified by the public or media
[6, 7]. A proactive approach has a number of advantages.
The surveillance system has already established baseline
frequency expectations and case ascertainment, which
makes the verification of any unusual aggregation of cases
relatively straightforward, a process which we also inte-
grate in the data quality strategy [11]. Detecting clusters
Table 2 Characteristics of 44 confirmed clusters
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Spina Bifida 2007 5 0.38 13.2 9 0.049 59 No Significant change
Cleft lip with or
without palate
2007 57 33.55 1.7 535 0.01 96 No Significant change
Congenital cataract 2008 6 0.43 14 30 \0.001 24 No Significant change
Ventricular septal
defect
2008 6 0.32 18.8 1 0.045 502 Significant non-linear change
Ventricular septal
defect
2008 18 4.6 3.9 50 0.012 140 Significant decreasing trend
Diaphragmatic
hernia
2008 7 1.39 5 176 0.024 12 No significant change
Hip dislocation and/
or dysplasia




2008 5 0.43 11.6 28 0.036 23 No significant change
Asplenia 2008 7 1.6 4.4 222 0.037 11 No significant change
Patau syndrome/
trisomy 13
2008 7 0.72 9.7 54 \0.001 21 No significant change
Klinefelters
syndrome
2008 17 6.87 2.5 455 0.013 23 No significant change
Anencephalus and
similar
2009 5 0.27 18.5 21 0.005 20 Significant non-linear change
Coarctation of aorta 2009 9 2.08 4.3 243 0.009 13 Not tested: too few cases
Choanal atresia 2009 6 0.89 6.7 113 0.021 12 Not tested: too few cases
Cleft palate 2009 5 0.16 31.3 2 0.007 125 No significant change
Bladder exstrophy
and/or epispadia
2009 5 0.92 5.4 174 0.039 8 Not tested: too few cases
Edward syndrome/
trisomy 18
2009 9 1.76 5.1 86 0.039 31 No significant change
Neural tube defects 2010 5 0.25 20 2 0.048 193 No significant change
Atrioventricular
septal defect
2010 5 0.58 8.6 62 0.039 14 Not tested: too few cases
Total anomalous
pulm venous return




2010 8 2.38 3.4 365 0.027 10 Not tested: too few cases
Renal dysplasia 2010 7 0.78 9 27 0.02 43 Significant non-linear change
Polydactyly 2010 54 30.56 1.8 532 \0.001 88 Significant decreasing trend
Patau syndrome/
trisomy 13
2010 9 2.33 3.9 239 0.029 15 Not tested: too few cases
Hydrocephaly 2011 5 0.4 12.5 19 0.042 33 No Significant change
Down Syndrome 2011 5 0.15 33.3 1 0.01 233 Significant increasing trend
Anencephalus and
similar
2012 9 1.32 6.8 27 0.024 73 No significant change
Transposition of
great vessels
2012 5 0.47 10.6 34 0.039 21 No Significant change
Cleft lip with or
without palate
2012 9 1.25 7.2 32 0.017 69 No significant change
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within a monitoring system avoids the silent multiple
comparison problem where a large number of communities
are implicitly monitoring their health but only the unusual
aggregations are reported [5, 29, 30]. It avoids expending
resources on following up suspected clusters which turn out
not to be unusual aggregations [6]. It also avoids con-
ducting an investigation in the difficult context of pressure
from media or community groups who have identified a
possible cluster. There have been no media or community
concerns expressed about the 44 ‘‘confirmed’’ clusters we
have detected, which are described in publicly available
monitoring reports and other dissemination materials, and
we believe that transparency is crucial.
Most registries or associated public health authorities,
after confirmation of the cluster by preliminary investiga-
tion, decided on further monitoring rather than proceeding
to full investigation. When further monitoring was done the
next year, the vast majority of clusters did not increase in
size, compatible with the clusters having been due to
chance or a time-limited local cause. The ‘‘wait and see’’
approach may be a justifiable way to use public health
resources most effectively, investing in continuing clusters
which are least likely to be due to chance and where ex-
posures, if real, are ongoing [31]. Nevertheless, the situa-
tion regarding public health response and triggering of full
investigations [32] is variable and unclear in many Euro-
pean countries. Full investigation need not focus narrowly
on the cluster, but investigate hypotheses in the wider
population, so that scientific and public health benefit will
result regardless of whether the cluster is finally fully ex-
plained [33, 34]. While we can be confident that the system
has shown that no introduction of a widespread and highly
teratogenic agent like thalidomide has occurred during this
time period, we recommend that public health authorities
in Europe develop clear protocols for response to CA
clusters generated by routine statistical monitoring which
have been confirmed by preliminary registry investigations.
We used expert review to help judge which clusters
were less likely to be chance events. Similar clusters co-
occurring in more than one registry would have been
considered an indication of a non-chance event, as would

























Cleft lip with or
without palate
2012 5 0.16 31.3 1 0.019 253 No significant change
Cleft palate 2012 7 0.93 7.5 64 0.019 23 No significant change
Omphalocele 2012 8 2.6 3.1 397 0.041 10 Not tested: too few cases
Renal dysplasia 2012 7 0.72 9.7 21 0.019 53 No significant change
Congenital
hydronephrosis
2012 15 4.09 3.7 101 0.027 61 Significant non-linear change
Bladder exstrophy
and/or epispadia
2012 7 1.17 6 197 \0.001 9 Not tested: too few cases
Club foot —talipes
equinovarus
2012 11 1.94 5.7 37 0.018 79 No significant change
Down syndrome 2012 9 1.45 6.2 43 0.026 51 No significant change
Coarctation of aorta 2013 12 4.78 2.5 486 0.036 15 Not tested: too few cases
Total anomalous
pulm venous return
2013 5 0.78 6.4 118 0.045 10 Not tested: too few cases
Ano-rectal atresia
and stenosis
2013 5 0.82 6.1 139 0.039 9 Not tested: too few cases
Hypospadias 2013 37 15.86 2.3 102 0.024 232 Significant non-linear change
Club foot—talipes
equinovarus
2013 6 0.56 10.7 5 0.049 144 Significant increasing trend
Patau syndrome/
trisomy 13
2013 5 0.35 14.3 5 0.037 77 No significant change
Turner syndrome 2013 14 2.14 6.5 34 \0.001 92 No significant change
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clustering at the same time, but neither of these circum-
stances occurred. Continuing clusters also indicate a non-
chance event. A key criterion for clinical geneticists was
diagnostic homogeneity. In the early years of monitoring,
many clusters were dismissed as heterogeneous, and this
led to a better system for separating genetic syndromes in
cluster detection. However, many known teratogens cause
a number of different types of CA, and heterogeneous
clusters with known exposures have been documented [35]
so the future will lie in more aetiologically relevant clas-
sification of CA.
Another criterion was the size of the Observed/Expected
ratio and associated p value. Neutra has suggested con-
centrating on clusters with a relative risk of 20 or more
since any common cause, if present, will be most readily
found by investigation [5]. The paradox, however, is that
the higher the Observed/Expected ratio or RR, the more
difficult it is to propose a plausible explanation [5]. In our
experience, these very high ratios were associated with
clusters of very short duration of 1 or 2 days which are
unlikely to relate to plausible time-limited exposures.
Moreover, day of conception was imprecisely estimated
from gestational week, and the statistical method is being
adjusted to reflect this.
The EMDP software enables registries to conduct more
intensive early monitoring after a cluster is detected. The
monitoring system can also be used reactively to speed up
response to concerns expressed by clinicians—for example
in 2006, a local concern about a seemingly unusual number
of reduction defects of the hand led the registry concerned
to intensify early data collection and monitoring of these
defects in advance of the usual timetable, and request other
registries to do so via EUROCAT Communications. This
suspected case aggregation was finally found not to be
unusual [36].
Use of the scan method which self-adjusts for multiple
testing across multiple window sizes reduces the false
positive rate, and the number of clusters detected was not
overwhelming. Data simulations showed that, since only
clusters in the most recent two of the 5 year period are
output, approximately 2.5 % of tests would detect eligible
clusters by chance [9]. The actual ‘‘detection rate’’ (i.e.
proportion of tests resulting in statistically significant
temporal clusters of cases) was 3.4 %, but only one-third
were confirmed as unusual aggregations, bringing the de-
tection rate below the chance detection rate. Cluster in-
vestigation concentrates on the cases ‘‘inside’’ the cluster,
but not those ‘‘outside’’—only cases within the cluster are
excluded due to data errors, thus clusters disappear but
cannot appear as a result of verification, leading to a lower
than chance detection rate of confirmed clusters. Another
issue may be a desire to explain a cluster as an artefact of
diagnostic or other change rather than be left with an
unexplained excess. Registry Leaders Meetings and expert
review are important for discussing these judgements.
Timeliness is one of the major issues we face. The
sensitivity of the cluster detection method to data com-
pleteness was shown by the high proportion of clusters
(up to 30 % of confirmed new clusters) which were
missed at the first monitoring opportunity, and only found
when data had been further updated with late or amended
diagnoses. We have found that earlier data transmission is
not feasible and have instead increased efficiency of the
statistical monitoring process. While monitoring across
healthcare databases in real time is becoming technically
feasible in some areas, speed would come at the expense
of noise relating to poorly standardised diagnosis and
coding of CA in healthcare data, missing and inaccurate
data, and absence of information about terminations of
pregnancy, thus increasing the false positive rate and re-
ducing the sensitivity of identification of clusters of
concern.
EUROCAT’s statistical monitoring covers 10 % of the
EU population, less than half of EUROCAT’s current
surveillance coverage. There is thus potential, particularly
with use of the EDMP by registries locally, to increase
population coverage.
We conclude that monitoring for CA clusters based on
date of conception is a useful and feasible part of surveil-
lance, particularly in relation to early detection of wide-
spread exposures with high teratogenicity, accompanied by
clear investigation protocols and expert review. The results
for 2007–2013 have been reassuring in terms of the ab-
sence of widespread, sudden and sustained temporal in-
crease in CA potentially caused by a new teratogenic
exposure. Temporal cluster detection is only one of the
various types of surveillance based on birth defect reg-
istries needed to detect teratogenic exposures in the
population, and one of the most limited in terms of pro-
gressing aetiologic understanding. However, when inte-
grated with a data quality improvement strategy, temporal
cluster detection need not be resource intensive and is a
useful public health tool, whether the results are negative
or positive in terms of finding a cluster of concern. The
greatest improvements to the temporal cluster detection
system would be greater timeliness of data availability,
greater clarity in local public health response protocols,
development of a more aetiologically-oriented CA classi-
fication system, and expansion of the participating Euro-
pean population.
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